SecBot SecBot
PRESS-RELEASE ·Filed Jun 10, 2026

TEVA

Teva Pharmaceutical Industries Ltd
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Expect positive sentiment on pipeline depth and growth narrative, though near-term P&L impact is limited until NDA filing and potential approval. Key catalyst: NDA acceptance and FDA review timeline in H2 2026. Monitor Phase 3 data details and competitive landscape in Tourette syndrome.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$33.58
T+0 close · Jun 10, 2026 · via day close
Latest settled
+9.01%
T+60 · $36.61
Vs SPY
+2.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 10 $33.58entry
  2. T+1 · 5mo ago +2.92%α +1.22% · $34.56
  3. T+5 · 5mo ago −2.00%α −5.43% · $32.91
  4. T+20 · 4mo ago −1.43%α −5.05% · $33.10
  5. T+60 · 2mo ago +9.01%α +2.43% · $36.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royalties, adding ecopipam, a late-stage, first-in-class D1 antagonist for pediatric Tourette syndrome. NDA submission is expected in H2 2026, and Phase 3 data published in JAMA Neurology showed statistical significance on the primary endpoint.

Key Financial Metrics

Deal Value
$700.0M

Key Facts

  • $700 million upfront consideration paid at closing
  • Up to $200 million in additional commercial milestone payments plus net sales-based royalties
  • Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations
  • Phase 3 Tourette syndrome study met primary endpoint with statistical significance (p = 0.0084) and was published in JAMA Neurology
  • NDA submission anticipated in second half of 2026
  • Expands Teva's innovative pipeline in neuroscience with significant unmet need, supporting the Pivot to Growth strategy

Financial Impact

$700M upfront + up to $200M milestones + royalties; Teva market cap ~$40B, so ~2.25% of market cap at risk upfront with upside from commercial milestones

rd_spendpipeline_valuefuture_revenue

Risk Factors

  • Regulatory risk: ecopipam may not gain FDA approval
  • Commercial risk: Tourette syndrome market is niche (Orphan Drug designation indicates <200K patients)
  • Integration and execution risk: Teva must successfully file NDA and launch a new neuroscience asset
  • Additional $200M milestone payments and royalties could pressure near-term cash flow if sales disappoint

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3309960

Track record

61 reports on TEVA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026